<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239054</url>
  </required_header>
  <id_info>
    <org_study_id>28028</org_study_id>
    <nct_id>NCT03239054</nct_id>
  </id_info>
  <brief_title>Prescribing Exercise as Medicine in Pregnancy</brief_title>
  <official_title>Prescribing Exercise as Medicine in Pregnancy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized controlled parallel arms trial. The purpose of this study is to&#xD;
      evaluate if prescribing exercise in pregnancy can change maternal behavior towards exercise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized controlled parallel arms trial. The purpose of this study is to&#xD;
      evaluate if prescribing exercise in pregnancy can change maternal behavior towards exercise.&#xD;
      Once screened and consented, participants will be randomized to either the intervention or&#xD;
      control group in a 1:1 fashion. The intervention group will receive the PARMED-X prescription&#xD;
      and the control group will receive routine care as usual. Physical activity will be monitored&#xD;
      with a Polar fitness tracking device.&#xD;
&#xD;
      Maternal and neonatal outcomes will be collected from the electronic medical record. Maternal&#xD;
      outcomes include demographics, total gestational weight gain, pre-pregnancy body mass index&#xD;
      (BMI), BMI at the time of delivery, mode of delivery, glucose screen value, presence or&#xD;
      absence of gestational diabetes and presence or absence of hypertensive disorders of&#xD;
      pregnancy. Neonatal outcomes include gestational age at delivery, birth weight, Apgar scores,&#xD;
      arterial cord blood gases.&#xD;
&#xD;
      Psychological outcomes will also be assessed using several validated scales in pregnancy&#xD;
      including The Edinburgh Postnatal Depression Scale (EPDS) and The State Trait Anxiety&#xD;
      Inventory (STAI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IRB issues&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>participants will be randomized in a 1:1 fashion into the study group or the control group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PARmed-X: Change in number of steps (physical activity level)</measure>
    <time_frame>1 year</time_frame>
    <description>change in number of steps (physical activity level)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PARMed-X: Gestational Weight Gain</measure>
    <time_frame>1 year</time_frame>
    <description>Gestational Weight Gain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the study group will complete the Parmed-X Pregnancy form and be provided with a prescription for exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group will be provided with the ACOG Pamphlet entitled &quot;Exercise during pregnancy&quot; and will be encouraged to become physically active during their pregnancy. They will receive routine care as scheduled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Physical activity</intervention_name>
    <description>pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>Information will be given as part of standard care</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 45 years of age&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Gestational age at or less than 20 0/7 weeks at the time of enrollment&#xD;
&#xD;
          -  Low risk pregnancy&#xD;
&#xD;
          -  Willing and able to participate in a more active lifestyle/exercise program&#xD;
&#xD;
          -  Smart phone able to add the &quot;Flow mobile app&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Twins or higher order multiple gestations&#xD;
&#xD;
          -  Known congenital anomaly&#xD;
&#xD;
          -  Underweight BMI ( BMI less than 18.50)&#xD;
&#xD;
          -  High risk pregnancy - ie. hypertension, pre-existing diabetes&#xD;
&#xD;
          -  Women with a known contraindication to exercise&#xD;
&#xD;
          -  Persistent 2nd or 3rd trimester vaginal bleeding&#xD;
&#xD;
          -  Hemodynamically significant heart disease&#xD;
&#xD;
          -  Restrictive lung disease&#xD;
&#xD;
          -  Incompetent cervix or cerclage&#xD;
&#xD;
          -  Placenta previa&#xD;
&#xD;
          -  Premature labor or rupture of membranes&#xD;
&#xD;
          -  Preeclampsia&#xD;
&#xD;
          -  Severe anemia&#xD;
&#xD;
          -  Poorly controlled hypertension, seizure disorder, or hyperthyroidism&#xD;
&#xD;
          -  Known intrauterine growth restriction&#xD;
&#xD;
          -  Not cleared for exercise by the &quot;Contraindications to Exercise from PARMED-X&quot; form&#xD;
&#xD;
          -  PAVS score greater than or equal to 150 minutes/week&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shilpa Babbar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Mary's Health Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>Shilpa Babbar, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

